Nika Pharmaceuticals, Inc. (NIKA) Latest Developments
Rhea-AI Summary
Nika Pharmaceuticals (OTCQB: NIKA) has released a report detailing the therapeutic effects of ITV-1 on volunteers with AIDS, cancer, and other diseases. The report highlights specific cases demonstrating the drug's curative effects and its potential applications beyond AIDS treatment.
In parallel developments, Nika Europe has made a second payment of $195,554 for the vial production line and is finalizing clean room design details. The factory construction is expected to be completed by the end of Q2 2025.
Positive
- Second payment of $195,554 received from Nika Europe for vial production line
- Factory construction progressing with completion expected by Q2 2025
- ITV-1 shows potential for broader therapeutic applications beyond AIDS
Negative
- Specific efficacy data and clinical trial results not disclosed in the report
- Timeline for regulatory approvals and commercialization not specified
HENDERSON, Nev., April 11, 2025 (GLOBE NEWSWIRE) -- Nika Pharmaceuticals, Inc. (OTCQB: NIKA) published a report on the therapeutic effect and potential economic impact of ITV-1. The document contains the company’s findings on the effects of the drug on volunteers suffering from AIDS, cancer and other diseases. It details several examples of the curative effect of ITV-1 and its wider applicability beyond AIDS. You can read the document here or on our website.
NIKA’s partner company, Nika Europe, has made the second
Dimitar Savov, NIKA’s CEO, stated: “Although we had previously published the results of the AIDS clinical trials, I believe that it is important to also share our observations with volunteers outside of the trials to present the impact of ITV-1 beyond pure statistics and into particular cases of people suffering from various diseases who ITV-1 has helped tremendously.”
About Nika Pharmaceuticals, Inc.
Nika Pharmaceuticals, Inc. (NIKA) is a pharmaceutical company, specializing in the treatment of HIV/AIDS, Hepatitis B and C, Rheumatoid Arthritis, Cancer, Diabetes, and all diseases, for which strengthened cell immunity is of vital importance. NIKA's intellectual property includes six drugs in injection form – two of which have successfully undergone clinical trials with good treatment results – four drugs in tablet form, and eleven dietary supplements. NIKA’s goal is to not only achieve corporate profits, but to provide better and easier access to life-saving medicinal drugs and useful dietary supplements. Find more on www.nikapharmaceuticals.com.
Forward-looking Statement:
This press release contains forward-looking statements. Certain statements, other than purely historical information, including estimates, projections, statements relating to our business plans, objectives, and expected operating results, and the assumptions upon which those statements are based, are “forward-looking statements.” These forward-looking statements generally are identified by the words “believes,” “expects,” “anticipates,” “intends,” “plan,” “may,” “will,” “would,” and similar expressions. Forward-looking statements are based on current expectations and assumptions that are subject to risks and uncertainties which may cause actual results to differ materially. Our ability to predict results or the actual effect of future plans or strategies is inherently uncertain.
CONTACT Clifford Redekop, Secretary COMPANY Nika Pharmaceuticals, Inc. PHONE (702)-326-3615 EMAIL info@nikapharmaceuticals.com WEB www.nikapharmaceuticals.com
FAQ
What are the latest developments for NIKA's ITV-1 drug treatment?
When will NIKA's new production facility be completed?
How much did Nika Europe pay for the vial production line?
What diseases can NIKA's ITV-1 potentially treat?
